Monday, November 09, 2026
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Overview. CoreCivic delivered strong financial results in a very active quarter, driven by increased demand for the Company’s services from ICE, including higher utilization of recently activated facilities, as well as the contribution from the acquisition of Clinical Solutions Pharmacy earlier this year. The Company’s capital allocation strategy also contributed to improved results through lower interest expense and a reduction in weighted average shares outstanding, which positively impacted per-share results.
3Q26 Results. Revenue of $744.1 million was up 28.2% year-over-year. We were at $690 million. Adjusted EBITDA was $117.8 million versus $88.8 million last year. We projected $110 million. Net income in 3Q26 was $1,344.1 million, or $14.49 per diluted share, compared with net income in 3Q25 of $26.3 million, or $0.24 per diluted share. Adjusted net income was $45.7 million, or $0.49 per diluted share, compared with $26.2 million, or $0.24 per diluted share, in 3Q25. We were at $0.43.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.